FELIP FELIP FENOGET FENOGET FENOGET FENOGET FENOGET ELMC ELMC ELMC ELMC ELMC EQULIP EQULIP TRIFIBE TRIFIBE FENOGAL FERNORAT FERNORAT FENORAT FENORAT FENORAT ZIBRATE TS ZIBRATE ZIBRATE LITVEA LITVEA LIPIDOF LIPIDOF FIBRA FENOCOR FENOCOR FENORATE LIPOFEN LIPOFEN

Dose: 160 mg
Single Dose: 160 (160)
Frequency: 24 hourly
Route: PO
Instructions: Low dose should be used in patients with renal insufficiency.

Fenofibrate (Micronized) is the derivative of Fenofibrate. It is of Synthetic origin. . The Molecular Weight of Fenofibrate is 360.80.

Fenofibrate is contraindicated in conditions like Gall stones,Liver diseases,Hypersensitivity,Pregnancy,Renal impairment.

The severe or irreversible adverse effects of Fenofibrate, which give rise to further complications include Hepatitis, Rhabdomyolysis.The symptomatic adverse reactions produced by Fenofibrate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Myalgia, Constipation, Skin rashes, Impotence, Decrease in libido.

Fenofibrate is primarily indicated in conditions like Hypercholesterolaemia, Hyperlipoproteinaemia, Prophylaxis of NSAID-associated gastric or duodenal ulcer, Prophylaxis of NSAID-associated gastric or duodenal ulcer.

Fenofibrate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCerivastatin SodiumCerivastatin sodium causes additive toxicity with fenofibrate These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Increased in Serum Aminotransferase

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Caps Store Below 25°C. Protect from Sunlight and Moisture.

Renal impairment (avoid if severe). MYOTOXICITY.Special care needed in patients with renal disease, as a progressive increase in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolosis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly. Hepatic impairment, liver function tests recommended every 3 months for first year (discontinue treatment if significantly raised). Correct hypothyroidism before initiating treatment.